Anti-CXCL8 antibody [311,312], CXCL8 small interfering RNA [313], and anti-CXCL1 antibody [314] have also been tested and such therapies have shown a reduction in tumor cell migration and angiogenesis. This evidence concerns the gene CXCL8 and neoplasm.